Welcome to our Investor Centre

Please click on the Profiles below to see more details on our other clients:

All of the information contained within this website has been compiled from sources believed to be reliable, but no warranty, expressed or implied, is given that the information is complete or accurate or that it is fit for a particular purpose. All such warranties are expressly disclaimed and excluded. Any opinions, recommendations and forecasts referred to are not those of Walbrook PR Limited but are expressly those of third parties, such as investment analysts and financial journalists. Such opinions, recommendations and forecasts may have been superseded and thus may not necessarily be the current opinions, recommendations and forecasts of the relevant analyst/broker. None of the content of this website should be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell, the securities of any listed Company mentioned or featured herein as it is for information only. Any recommendations referred to by third parties do not necessarily imply the suitability of particular securities for individual situations. The value of securities and the income from them may fluctuate. It should be remembered that past performance is not necessarily a guide to future performance. You are strongly advised to seek guidance from a professional investment adviser before entering into any contract to buy or sell any security featured herein. By reading this disclaimer, and ticking the box below, you confirm that you accept and understand its content, and that you shall not hold Walbrook PR Limited, its directors and staff nor any of its subsidiaries or connected companies liable for any loss that you may sustain should you decide to buy or sell any of the mentioned securities.

Renalytix AI plc

Company Profile

Company website
Medical Equipment and Services (Medical Equipment)
A developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company uses AI to analyse different sources of information including blood-based biomarkers, genetics and large electronic health record data bases to improve diagnosis and clinical management of kidney disease. The Company is a spin-out of AIM-listed EKF Diagnostics Holdings plc and it's lead product KidneyIntelX™, which is being developed in close collaboration with Mount Sinai and other large US academic medical centres, is due to launch in 2019.

Investor Access Events

09 Mar
Event information
Investor presentation
Brand Exchange, 3 Birchin Lane, London EC3V 9BW
Monday, 9th March 2020, 5.15pm for a 5.30pm start